Chuikyo Debate on FY2026 Drug Pricing Reform

• MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?
  December 4, 2025

• MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
  December 4, 2025

• FY2026 Reform Roadmap Keeps Key Drug Pricing Issues on Ice, Snubs Many Industry Requests: Chuikyo
  December 4, 2025

• Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
  December 3, 2025

• Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
  November 20, 2025

• Chuikyo Split over How to Ease Negative Margins
  November 20, 2025

• Providers Urging Possible Price Measures over Packaging Misalignment
  November 20, 2025

• Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
  November 20, 2025

• Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
  November 20, 2025

• Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
  November 17, 2025

• Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines
  November 13, 2025

• Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
  November 13, 2025

• Tepid Exchanges at Chuikyo over Public-Private Working Group Report
  November 6, 2025

• Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
  October 30, 2025

• Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
  October 30, 2025

• FIRM Urges Continued Premiums for Conditionally Approved Regenerative Medicines
  October 30, 2025

• Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
  October 30, 2025

• No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
  October 20, 2025

• Payers, Providers Clash over Fate of Fee Premiums for Generic Use
  October 20, 2025

• Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
  October 16, 2025

ページ